Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4973721 | 0.90 | SMN1; SMN2 (0.51) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL3031541 | 0.84 | KMT2A (0.67) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL3041094 | 0.84 | MEN1 (0.67) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL3044840 | 0.84 | MEN1 (0.67) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL4453414 | 0.83 | MEN1 (0.66) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL3042107 | 0.83 | SMN1; SMN2 (0.64) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL3039155 | 0.83 | SMN1; SMN2 (0.64) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL4978408 | 0.83 | L3MBTL1 (0.57) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL3045797 | 0.83 | MEN1 (0.62) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL3042144 | 0.82 | MEN1 (0.64) | ALDH1A1MEN1KMT2AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645784-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2010-01-12 | — | — | US | claimed |
| EP-2042490-A2 | Benzimidazole derivatives as vanilloid receptor antagonists | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | claimed |
| EP-1626964-B1 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | claimed |
| US-20060287377-A1 | New benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | claimed |
| CN-1784387-A | Novel benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-06-07 | — | — | CN | claimed |
| EP-1626964-A2 | NEW BENZIMIDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2006-02-22 | — | — | EP | claimed |
| WO-2004100865-A2 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | WO | claimed |
| US-7645784-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2010-01-12 | — | — | US | disclosed |
| EP-2042490-A2 | Benzimidazole derivatives as vanilloid receptor antagonists | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| EP-1626964-B1 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20060287377-A1 | New benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| CN-1784387-A | Novel benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-06-07 | — | — | CN | disclosed |
| EP-1626964-A2 | NEW BENZIMIDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004100865-A2 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287377-A1 | New benzimidazole derivatives | CYP2C9, CDK9, CCNI | ALDH1A1 668/4885MEN1 1947/4885KMT2A 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.